Fluconazole

Evidence Level: L5

Predicted Indications: 1

Fluconazole

Pharmacist Assessment Report

Fluconazole: From Candidiasis to Punctate Epithelial Keratoconjunctivitis

One-Sentence Summary

Fluconazole is an azole antifungal originally used to treat candidiasis (oral, oesophageal, vulvovaginal, and invasive forms) and cryptococcal meningitis. The TxGNN model predicts it may be effective for punctate epithelial keratoconjunctivitis, but currently there are 0 clinical trials and 0 publications supporting this direction, so the prediction rests on the model alone.

Quick Overview

Item	Content
Original Indication	Oral candidiasis, candidiasis, vulvovaginal candidiasis, oesophageal candidiasis, cryptococcal meningitis, candidaemia, disseminated candidiasis
Predicted New Indication	Punctate epithelial keratoconjunctivitis
TxGNN Prediction Score	0.9924
Evidence Level	L5
India Market Status	Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data
Number of Listed Products	at least 20
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on known information, fluconazole is an azole antifungal that inhibits fungal CYP51 (lanosterol 14-alpha-demethylase) and blocks ergosterol synthesis. Its efficacy in superficial and invasive fungal infections is established.

The link to the new indication is weak. Punctate epithelial keratoconjunctivitis is most often viral (for example adenovirus) or related to dry eye, drug toxicity, or other non-fungal causes. An antifungal mechanism therefore has no clear connection to the typical cause. A plausible link would exist only for a fungal subset of keratoconjunctivitis, and the supplied data do not support that.

The high score (0.9924) comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence. The prediction should be regarded as a hypothesis only.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

India Market Information

Fluconazole is marketed in India with 20 valid single-ingredient registrations and no cancelled ones. The approved indication text is not available for these registrations. The main authorizations are:

Authorization Number	Product Name	Dosage Form	Manufacturer
234535	V Can 150mg Capsule	Strip of 1 capsule	Pegasus Farmaco India Pvt Ltd
87481	Flucowin Tablet	Strip of 1 tablet	Makers Laboratories Ltd
146110	M Fluk 150mg Tablet	Strip of 10 tablets	Madhav Biotech Pvt. Ltd
89362	Flucar 200 Capsule	Strip of 4 capsules	Cartel Laboratories
39101	Cozen 150mg Tablet	Strip of 1 tablet	Zenith Healthcare Ltd

All listed forms are oral (capsules and tablets). No topical or ophthalmic fluconazole product appears among the registrations, so route compatibility with an eye indication would need to be assessed separately.

Safety Considerations

Contraindications (from knowledge graph, not label text): Long QT syndrome, familial long QT syndrome, kidney disease, pyoureter, liver disease, gallbladder disease.
Drug Interactions: 783 interactions were recorded. Examples:
- Major: Chlorpropamide.
- Moderate: Famotidine, rabeprazole, omeprazole, dexlansoprazole, hydrocortisone, dexamethasone, betamethasone, triamcinolone, budesonide, loperamide, aprepitant, saxagliptin, bisacodyl.
- Minor: Amphotericin B, clarithromycin.

Please refer to the package insert for warnings and label contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by the model score, with no clinical trials or literature. The antifungal mechanism does not fit the usual non-fungal causes of this condition, and no ophthalmic fluconazole product is registered in India.

To proceed, the following is needed:

Mechanism of action data and a clearer mechanistic rationale for the proposed indication
Literature and trial searches for fluconazole in fungal keratitis or keratoconjunctivitis, to find any supporting subset
Package insert warnings and contraindications from the India regulatory source, since the safety screen cannot proceed without them
Assessment of route and formulation (oral versus ophthalmic) for an ocular use
Review of the knowledge-graph contraindications (QT prolongation, renal and hepatic disease) against a possible ocular use
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.